Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-04-20
DOI
10.1002/ijc.31547
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data
- (2018) Henning Reis et al. DISEASE MARKERS
- Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative Operation
- (2018) Ruiqi Liu et al. Biomed Research International
- Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma
- (2017) Jen-Fan Hang et al. PATHOLOGY
- Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer
- (2017) Sebastian Thiem et al. PATHOLOGY INTERNATIONAL
- Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
- (2016) Soojin Cha et al. BMC CANCER
- Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma
- (2016) Kah Poh Loh et al. Clinical Genitourinary Cancer
- Clinical Sequencing-guided Therapy of Urachal Carcinoma: New Perspective for a Rare Cancer
- (2016) Péter Nyirády et al. EUROPEAN UROLOGY
- Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
- (2016) Ana Collazo-Lorduy et al. EUROPEAN UROLOGY
- PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
- (2016) Matthew W Rosenbaum et al. MODERN PATHOLOGY
- Clinical, prognostic, and therapeutic aspects of urachal carcinoma—A comprehensive review with meta-analysis of 1,010 cases
- (2016) Tibor Szarvas et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations
- (2016) Harshabad Singh et al. Oncotarget
- Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
- (2016) Orsolya Módos et al. Oncotarget
- Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression
- (2015) Murugabaskar Balan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas
- (2015) H. Reis et al. LUNG CANCER
- Targeting Oncogenic Mutant p53 for Cancer Therapy
- (2015) Alejandro Parrales et al. Frontiers in Oncology
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
- (2014) Christina Therkildsen et al. ACTA ONCOLOGICA
- Telomerase Reverse Transcriptase Gene Promoter Mutations Help Discern the Origin of Urogenital Tumors: A Genomic and Molecular Study
- (2013) Song Wu et al. EUROPEAN UROLOGY
- High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations
- (2013) S. Joseph Sirintrapun et al. HUMAN PATHOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Frequency of TERT promoter mutations in human cancers
- (2013) João Vinagre et al. Nature Communications
- Urachal Carcinomas of the Nonglandular type
- (2012) Gladell P. Paner et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Urachal Carcinoma
- (2009) Anuradha Gopalan et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started